

**Listing of Claims**

The following list of claims will replace all prior versions and listings of claims in the application.

1-11. (Canceled)

12. (Currently Amended) A method of treating a solid vascularized tumor in a subject in need of such treatment, comprising administering cisplatin in conjunction with erythropoietin, wherein said erythropoietin is administered in an amount effective to enhance suppression of endothelial growth associated with administration of said cisplatin and wherein said subject is afflicted with or at risk of developing a solid vascularized tumor selected from cerebellar hemangioblastoma, ductal carcinoma of the breast or squamous cell cancer of the larynx.

13. (Previously Presented) A method according to claim 12, wherein said erythropoietin is administered concurrently with said cisplatin.

14. (Previously Presented) A method according to claim 12, wherein said erythropoietin is administered prior to said cisplatin.

15. (Previously Presented) A method according to claim 12, wherein said erythropoietin is administered after said cisplatin.

16-18. (Canceled)

19. (Previously Presented) A method according to claim 12, wherein said cisplatin is administered intravenously.

20. (Original) A method according to claim 12, wherein said erythropoietin is administered intravenously.

21. (Currently Amended) A method of treating a solid vascularized tumor in a

subject in need of such treatment, comprising administering cisplatin in conjunction with erythropoietin;

wherein said erythropoietin is administered in an amount of from about 750 Units per kilogram to about 2,000 Units per kilogram and said subject is afflicted with or at risk of developing a solid vascularized tumor selected from cerebellar hemangioblastoma, ductal carcinoma of the breast, or squamous cell cancer of the larynx.

~~wherein said erythropoietin is administered in an amount of from about 750 Units per kilogram to about 2,000 Units per kilogram.~~

22. (Canceled)

23. (Previously Presented) A method according to claim 21, wherein said erythropoietin is administered concurrently with cisplatin.

24. (Original) A method according to claim 23, wherein said cisplatin is administered intravenously.

25. (Original) A method according to claim 24, wherein said erythropoietin is administered intravenously.

26. (Previously Presented) A method according to claim 12, wherein said cisplatin is administered in a manner selected from the group consisting of intravenous, intramuscular, intraperitoneal, subcutaneous, intratumor, and intrapleural injection.

27. (New) A method of treating a condition associated with abnormal angiogenesis in a subject in need of such treatment, comprising administering erythropoietin in conjunction with a chemotherapeutic agent, wherein said erythropoietin is administered in an amount effective to enhance suppression of endothelial growth.

28. (New) The method of claim 27, wherein the chemotherapeutic agent is cyclophosphamide.

29. (New) The method of claim 27, wherein the chemotherapeutic agent is cisplatin.

30. (New) The method of claim 27, wherein said subject is afflicted with or at risk of developing a condition associated with abnormal angiogenesis selected from diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis or psoriasis.